-
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
NCT06106906 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
NCT06106893 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07444307 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 3 locations
-
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
NCT07363590 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 21 locations
-
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
NCT07413341 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
NCT06943937 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07123519 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978 ·
Phase: Phase 1 ·
Ages: 12 Years to 70 Years ·
Sex: All (male and female) · 21 locations
-
A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
NCT07491900 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 19 locations
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
NCT06625671 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 7 locations
-
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 18 locations
-
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 16 locations
-
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
NCT06182969 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: Female · 1 location
-
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT06249438 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 20 locations
-
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
NCT06857214 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
A Study of GR1803 in Systemic Lupus Erythematosus
NCT07348055 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
NCT06576271 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 28 locations
-
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
NCT07371468 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 19 locations
-
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 28 locations
-
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
NCT06917742 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 3 locations
-
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
NCT07331272 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 5 locations
-
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07276958 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 9 locations
-
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 14 locations
-
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
NCT07749651 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07607964 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 10 locations
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
NCT06977724 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 11 locations
-
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 12 locations
-
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
NCT06647069 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 6 locations
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 37 locations
-
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104 ·
Phase: Phase 1 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female) · 17 locations
-
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 20 locations
-
Alnuctamab for Refractory SLE (LATTE Study)
NCT07219563 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07236762 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
NCT06685042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514 ·
Phase: Phase 1, Phase 2 ·
Ages: 3 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
NCT06710717 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
NCT07361094 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 2 locations
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
NCT06340750 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
NCT06789107 ·
Phase: Phase 1 ·
Ages: 5 Years and older ·
Sex: All (male and female) · 2 locations
-
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT07305116 ·
Phase: Phase 1 ·
Ages: 3 Years and older ·
Sex: All (male and female) · 1 location
-
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
NCT06941129 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
NCT07315087 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
NCT06347718 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
NCT07432334 ·
Phase: Phase 1 ·
Ages: 16 Years to 55 Years ·
Sex: All (male and female) · 1 location
-
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947460 ·
Phase: Phase 1, Phase 2 ·
Ages: 10 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
NCT06839976 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 29 Years ·
Sex: All (male and female) · 1 location
-
CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
NCT06349343 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT06822881 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
NCT06400537 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 2 locations
-
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 17 locations
-
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
NCT06892145 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female) · 3 locations
-
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
NCT06975787 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 18 locations
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
NCT06032923 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: Female · 1 location
-
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
NCT05508009 ·
Phase: Phase 1, Phase 2 ·
Ages: 1 Year to 30 Years ·
Sex: All (male and female) · 1 location
-
Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
NCT06691152 ·
Phase: Phase 1 ·
Ages: 5 Years and older ·
Sex: All (male and female) · 1 location
-
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
NCT06801119 ·
Phase: Phase 1 ·
Ages: 18 Years to 69 Years ·
Sex: All (male and female) · 1 location
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT07262983 ·
Phase: Phase 1 ·
Ages: 12 Years to 120 Years ·
Sex: All (male and female) · 1 location
-
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
NCT07236801 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
FT839 in Autoimmune Diseases
NCT07800871 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
NCT06350110 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
IASO-782 in Systemic Lupus Erythematosus
NCT07483346 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 4 locations
-
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
NCT06826430 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
NCT06675422 ·
Phase: Phase 1, Phase 2 ·
Ages: 14 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
MB-CART19.1 in Refractory SLE
NCT06189157 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
NCT06676631 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
NCT06581562 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
NCT07085676 ·
Phase: Phase 1 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 2 locations
-
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
NCT07237659 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 7 locations
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
NCT06434363 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
NCT06717815 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 17 locations
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
NCT06465147 ·
Phase: Phase 1 ·
Ages: 2 Years to 30 Years ·
Sex: All (male and female) · 1 location
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
NCT06121297 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 23 locations
-
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
NCT07523542 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
NCT06056921 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus
NCT05018858 ·
Phase: Phase 1 ·
Ages: No age limits stated ·
Sex: All (male and female) · 2 locations
-
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
NCT07031713 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
NCT07136389 ·
Phase: Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
NCT06657703 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female) · 3 locations
-
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
NCT06428188 ·
Phase: Phase 1, Phase 2 ·
Ages: 21 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 34 locations
-
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
NCT06934447 ·
Phase: Phase 1 ·
Ages: 5 Years and older ·
Sex: All (male and female) · 1 location
-
Study of CD19 CAR-T Therapy for Refractory SLE
NCT07403097 ·
Phase: Phase 1 ·
Ages: 5 Years and older ·
Sex: All (male and female) · 1 location
-
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
NCT07455578 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 6 locations
-
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
NCT07318259 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07331467 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07233642 ·
Phase: Phase 1 ·
Ages: 5 Years and older ·
Sex: All (male and female) · 1 location
-
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 260 locations
-
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
NCT06285279 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
NCT07185269 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
Showing 100 of 108 recruiting trials.